Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medinet Co's Other Operating Expense for the
three
months ended in Mar. 2026 was 円352.4 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,486.7 Mil.
Medinet Co's quarterly Other Operating Expense
increased
from Sep. 2025 (円344.7 Mil) to Dec. 2025 (円394.0 Mil) but then
declined
from Dec. 2025 (円394.0 Mil) to Mar. 2026 (円352.4 Mil).
Medinet Co's annual Other Operating Expense
declined
from Sep. 2023 (円1,524.2 Mil) to Sep. 2024 (円1,497.5 Mil) but then
increased
from Sep. 2024 (円1,497.5 Mil) to Sep. 2025 (円1,555.2 Mil).
Medinet Co Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Medinet Co's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,486.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円1,486.7 Mil mean?
Medinet Co (TSE:2370) has a Other Operating Expense of 円1,486.7 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Medinet Co and its competitors.
Is Medinet Co's Other Operating Expense too high?
Medinet Co's current Other Operating Expense is 円1,486.7 Mil. Overall, Medinet Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medinet Co's Other Operating Expense compare to VRTX and REGN?
Medinet Co's Other Operating Expense of 円1,486.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Medinet Co and its competitors. Medinet Co's current Other Operating Expense is 円1,486.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinet Co stock overvalued right now?
Based on GuruFocus' analysis, Medinet Co (TSE:2370) is currently considered Possible Value Trap. The stock's GF Value™ is 円41.68, compared to a current price of 円25.00 — trading 40% below its estimated fair value. The current Other Operating Expense is 円1,486.7 Mil. Medinet Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Medinet Co (TSE:2370), the current Other Operating Expense is 円1,486.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinet Co (TSE:2370) Overvalued in 2026?
Based on GuruFocus' analysis, Medinet Co stock appears to be undervalued.
The current stock price of 円25.00 is trading 40% below its estimated GF Value™ of 円41.68.
GuruFocus considers Medinet Co to be Possible Value Trap.
Key valuation signals for TSE:2370:
Other Operating Expense: 円1,486.7 Mil
GF Value™: 円41.68 vs. price of 円25.00 (40% below fair value)
No single metric tells the full story. See the TSE:2370 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinet Co Ltd is a Japan-based Contract Development and Manufacturing Organization (CDMO). The company is engaged in the research and development of regenerative medical products, investigational products, and specified cell products. MEDINET is a one-stop regenerative medicine and cell therapy solution provider. It provides value chain solutions including personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management solutions to medical institutions, research institutions, and biopharmaceutical companies.
42GF Score
Get the complete analysis for TSE:2370
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2370 has been successfully added to your 
